Andromeda Robotics
Personalized robot companions for aged care and assisted living residents to improve wellbeing.
Website: https://andromedarobotics.ai/
Cover Block
From the public record
| Field | Value |
|---|---|
| Name | Andromeda Robotics |
| Tagline | Personalized robot companions for aged care and assisted living residents to improve wellbeing. |
| Headquarters | Melbourne, Australia |
| Founded | 2022 |
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Robotics |
| Geography | Oceania |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | $10M+ |
| Total Disclosed Funding | ~$27,000,000 |
Links
From the public record
- Website: https://andromedarobotics.ai/
- LinkedIn: https://au.linkedin.com/company/andromedarobotics
The Short Version
PUBLIC Andromeda Robotics builds humanoid companion robots for aged care and healthcare, and it merits investor attention now because it has moved beyond concept-stage storytelling into named deployments, a larger disclosed funding base, and an early U.S. go-to-market push [Andromeda Robotics, September 2025] [RobotToday] [Built In]. The company was founded in Melbourne in 2022 by Grace Brown, who has linked the origin to loneliness she observed during the city’s COVID lockdowns, a framing that aligns closely with the company’s initial wedge in residential aged care rather than general-purpose robotics [SmartCompany] [Forbes, 2022].
Abi, the company’s flagship product, is positioned as a personalized humanoid companion robot intended to provide companionship and daily social and cognitive support for older adults, with differentiation resting less on automation and more on emotional engagement, personality design, and facility-level deployment in care settings [Andromeda Robotics] [National Seniors Australia]. Publicly cited customer activity suggests some traction in Australian aged care, including a mecwacare deployment described as spanning 22 homes and reported use with Medical & Aged Care Group sites, although most product-performance claims still trace back to the company or partner channels rather than independent clinical or economic outcomes data [RobotToday] [Upstarts Media] [mecwacare].
Brown’s background as a mechatronics engineer who has reportedly been building robots since age 15 is relevant here because the product sits at the intersection of hardware, behavior design, and care-environment usability, where technical execution and form factor both matter [SmartCompany] [Forbes Australia]. On capitalization, the public record supports a $1 million pre-seed in 2023 led by Galileo Ventures, a $3 million seed in 2024 led by Purpose Ventures, and a $23 million Series A announced in September 2025, with investors reported to include Forerunner Ventures, Main Sequence, Rethink Impact, Visible Ventures, NOAB Ventures, and Startmate; the disclosed business model is best read as hardware plus software sold into institutional care environments [Andromeda Robotics, September 2025] [Andromeda Robotics] [RobotToday] [Crunchbase].
Over the next 12 to 18 months, the points that matter most are whether Andromeda can convert pilot-style visibility into repeatable multi-site deployments, whether U.S. expansion produces named customers beyond the initial Eskaton partnership, and whether manufacturing scale keeps pace with the company’s stated deployment ambitions [Andromeda Robotics] [Forbes] [SmartCompany]. The current opening of U.S. sales and robot-behavior engineering roles supports the view that management is investing simultaneously in commercial expansion and product reliability, which is directionally encouraging but still early relative to the proof investors usually want in care delivery markets [Built In] [Indeed].
Unconfirmed -- This section mixes two-source confirmation for founding, funding, and some deployments with several material company-sourced product and traction claims that are not yet independently corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Robotics |
| Geography | Oceania |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | $10M+ total disclosed, approximately $27,000,000 |
The Company in Brief
PUBLIC
Andromeda Robotics presents as a young company with an unusually clear commercial thesis for its age: use humanoid companion robots to address loneliness and wellbeing in care settings, starting from Australia rather than a lab-to-industry licensing path. The company is based in Melbourne and was founded in 2022, with Grace Brown identified publicly as founder and CEO on the company website and Crunchbase [Andromeda Robotics] [Crunchbase]. The website describes the business as building personalized robot companions for aged care and assisted living residents, which is a narrower and more operationally specific positioning than the broader social robotics category often implies [Andromeda Robotics].
The public chronology is short but readable. Brown is listed by Forbes as having founded the Melbourne-based company in 2022, and Crunchbase also records 2022 as the founding year [Forbes, 2022] [Crunchbase]. By 2024, the company was publicly discussing seed financing and scaling production, and by September 2025 it had announced a $23 million Series A to accelerate deployments and manufacturing capacity [Andromeda Robotics, September 2025]. The legal entity name is not established in the cited public materials used here, so the overview rests on the operating brand and company profile rather than a registry extract [Andromeda Robotics] [Crunchbase].
Single-source, plausible -- Confirmed in part by Crunchbase and the company website, with founding date corroborated by Forbes; legal entity details were not established from the permitted source set.
What They Have Built
MIXED
Andromeda Robotics is selling a companion robot before it is selling a broader platform, and that distinction matters. Public materials consistently describe Abi as a humanoid robot built for aged care and healthcare settings, with the product centered on companionship, emotional interaction, and daily social or cognitive support rather than physical automation [Andromeda Robotics, Unknown] [Reuters, 2025-07-20]. In the company and partner descriptions reviewed, Abi is presented as a personalized companion for older adults, including residents living with dementia and those from culturally and linguistically diverse backgrounds, with deployments framed around wellbeing and engagement inside care environments rather than clinical intervention [National Seniors Australia] [mecwacare] [Andromeda Robotics, Unknown].
The product details that recur across public sources are specific enough to sketch the user experience, if not the full technical architecture. Reuters footage and related coverage describe a robot with eyes, arms, and legs, personality modes such as philosophical or motivational interactions, and even expressive features like bubble blowing from an arm-mounted device, all of which point to a deliberately anthropomorphic design aimed at eliciting social response [Reuters, 2025-07-20] [diginomica]. The company also says Abi can adapt to a resident's personality, ability, and language, and that customization will extend through an upcoming Abi app with selectable archetypes such as motivational coach or salesperson, although those personalization claims remain company-sourced and should be treated as product positioning rather than independently verified performance data [Andromeda Robotics, Unknown] [Andromeda Robotics, Unknown].
The underlying stack is only partially visible in public evidence, so the safer read is capability-first rather than architecture-first. Job postings suggest internal work on robot behavior and decision-making, mission autonomy, simulation, safety degradation, deployment, monitoring, and evaluation, which implies a software layer for behavioral orchestration and fleet support beyond the physical robot itself (inferred from job postings) [Built In] [Indeed]. The same postings, alongside the company's warehouse expansion and larger manufacturing footprint, also indicate that Andromeda is building both hardware production capacity and the software needed to manage robots in live care settings, but the public record does not establish model choices, on-device versus cloud processing, or the extent of remote operations tooling [SmartCompany] [Built In].
Single-source, plausible -- Product positioning is corroborated across company materials, Reuters, and partner references, but several personalization and feature claims remain company-sourced or inferred from job postings.
Market Size and Demand
PUBLIC
This market matters now because aged-care providers are under pressure to improve resident wellbeing without adding labor-intensive services, and companion robotics sits at the intersection of that demand and a broader push toward technology-enabled care delivery [SmartCompany] [National Seniors Australia].
The public sizing evidence is still thin, which limits precision on market size. The cleanest third-party figure in the source set is an eldercare robot market estimate of $3.56 billion in 2026, growing at 12.5% CAGR, according to RoboZaps [RoboZaps, 2026]. That is useful as a directional marker rather than a full underwriting base, because the report excerpt does not break out companion robots from broader eldercare robotics. For Andromeda specifically, the addressable segment appears narrower: residential aged care, assisted living, memory care, and selected hospital use cases where a humanoid social interface may matter more than industrial automation or back-office software [RobotToday] [Andromeda Robotics].
| Market segment | Size / growth claim | Source |
|---|---|---|
| Eldercare robot market | $3.56B in 2026 | [RoboZaps, 2026] |
| Eldercare robot market | 12.5% CAGR | [RoboZaps, 2026] |
from the limited sizing data is straightforward: there is evidence of a real category with growth, but not enough public detail here to map a precise TAM, SAM, and SOM for social companion robotics. Investors should treat broad eldercare robotics figures as analogous rather than as a direct measure of Andromeda's immediate market.
Demand drivers in the cited record are more concrete than top-down market math. The company and its partner materials repeatedly frame loneliness, social engagement, dementia support, and culturally responsive interaction as the core use cases in aged care [SmartCompany] [mecwacare]. That framing is consistent with reported deployments across mecwacare's 22 homes and usage across three of Medical & Aged Care Group's 11 homes in Victoria, which suggests operators are at least willing to trial non-clinical robotics if the product can slot into wellbeing programs rather than replace care staff [RobotToday] [Upstarts Media]. The product's emphasis on personalization, language adaptation, and distinct personality modes also points to a demand pattern closer to resident engagement software and therapeutic recreation tools than to conventional service robotics [Andromeda Robotics] [Reuters].
The adjacent markets are sizable and strategically relevant even if the current wedge is narrower. One adjacency is digital therapeutics and resident-engagement software used by aged-care operators, where the buying center may overlap with wellbeing and operations teams rather than clinical procurement. Another is pediatric and hospital companionship, which Andromeda has referenced publicly, though the public deployment evidence in this source set remains more substantial in aged care than in hospitals [Andromeda Robotics]. A third substitute is human-delivered lifestyle and companionship programming, which remains the incumbent standard and sets the practical budget ceiling for robotic companions even when the product is positioned as augmentation rather than labor replacement [National Seniors Australia] [mecwacare].
Macro and regulatory forces cut both ways. On the supportive side, providers are under pressure to demonstrate quality-of-life outcomes for residents, and technology that can extend social and cognitive support may receive a receptive hearing if it is safe, reliable, and easy for staff to adopt [National Seniors Australia] [mecwacare]. On the constraining side, this is still a hardware-and-software category operating in care settings, which usually means longer sales cycles, heightened scrutiny around safety, privacy, and efficacy, and a need for evidence that deployments improve resident experience without adding operational friction. The source set also points to expansion into the U.S. through a first partnership at Eskaton Village Carmichael, which introduces a larger buyer base but also a more complex regulatory and go-to-market environment than Australia alone [Andromeda Robotics].
Single-source, plausible -- Market sizing in this section relies primarily on one third-party source, with demand signals partially corroborated by provider and company materials.
Who Else Is Fighting for This
MIXED Andromeda Robotics is positioned less against a single named robotics peer than against a broad set of alternatives for resident engagement in aged care, with the company betting that a humanoid, personalized companion robot can win budget where facilities might otherwise buy staff-led programs, tablets, or lighter-weight engagement tools [Andromeda Robotics] [RobotToday].
The public record here is notably thin on direct peer naming, which matters because the company is already selling into an established care delivery environment rather than creating a greenfield budget line. On one side sit incumbent aged-care operators and wellbeing programs that address loneliness through human staff, activity coordinators, and existing facility programming; the sources explicitly place Abi inside provider wellbeing motions at groups including mecwacare and MACG, which suggests Andromeda is often competing for operating attention before it is competing for a robotics line item [mecwacare] [Upstarts Media]. On the other side are adjacent digital substitutes such as apps, screens, and non-humanoid assistive tools, while the company is trying to differentiate on embodied interaction, personalization, and emotional engagement rather than pure task automation [Andromeda Robotics] [National Seniors Australia] [Reuters, 2025-07-20].
Andromeda's edge today appears to be early distribution inside Australian aged-care settings, combined with a product form factor that is unusual enough to stand out in procurement conversations. The strongest public proof point is deployment breadth with mecwacare across 22 homes, alongside smaller reported penetration at MACG and earlier trials with Allity, part of Bolton Clarke Group [RobotToday] [Upstarts Media] [Andromeda Robotics]. That edge is meaningful but still perishable: distribution in care is durable only if deployments convert into repeatable outcomes, reference accounts, and serviceability at scale, and the current public evidence leans more heavily on deployment announcements than on retention, utilization, or measured resident outcomes [RobotToday] [Andromeda Robotics].
The company is most exposed where larger or better-capitalized alternatives can offer a simpler buying motion. A care provider can continue to fund conventional wellbeing staff and programming without taking hardware risk, and U.S. expansion adds another layer because Andromeda has public evidence of an initial partnership at Eskaton but not yet the same network density it has built in Australia [Andromeda Robotics]. Capital helps, and the company has disclosed $1 million pre-seed, $3 million seed, and a $23 million Series A, with the Series A investor group reported to include Forerunner Ventures, Main Sequence, Rethink Impact, Visible Ventures, Purpose Ventures, Galileo Ventures, NOAB Ventures, and Startmate [Andromeda Robotics, September 2025] [RobotToday]. Still, capital is not the same as channel control, and no public source here shows that Andromeda owns a dominant reseller, health system channel, or regulatory moat that would keep substitute solutions out.
Over the next 18 months, the most plausible competitive outcome is that the local winner is the vendor that can turn pilots and facility-wide deployments into a standard operating budget item rather than a novelty purchase. If mecwacare-style multi-site rollouts continue and the company's stated goal of 100 Abi units in nursing homes over 18 months is met, Andromeda is the clearest winner on the evidence available because it would move from demonstration to installed base leadership in its disclosed segment [RobotToday] [Andromeda Robotics] [Forbes]. If that target slips and U.S. expansion remains limited to isolated partnerships, the likely loser is not a named robotics rival in the public record but the broader humanoid companion robot category inside aged care, because buyers may default back to staff-led programs and lighter-weight digital engagement tools that carry less operational complexity [Andromeda Robotics] [Reuters, 2025-07-20].
Single-source, plausible -- Competitive analysis is constrained by the absence of named direct competitors in the provided public sources; company positioning and deployment claims are partially corroborated by RobotToday, mecwacare, Upstarts Media, Reuters, and company materials.
Opportunity
PUBLIC The prize here is unusually large for a young robotics company: if Andromeda Robotics can turn Abi from a pilot-led companion device into a standard layer inside aged-care operations, it could become one of the first scaled platform companies in social robotics for institutional care, in a market one industry report sizes at $3.56 billion in 2026 [RoboZaps, 2026].
The headline opportunity is not consumer robotics in the abstract. It is a narrower, more reachable position: becoming the default companion robotics provider for residential aged care, then extending that installed base into adjacent healthcare settings. That outcome is still early, but it is not purely aspirational because the public record shows three pieces that matter in sequence: named aged-care deployments and trials, including mecwacare across 22 homes and activity with Medical & Aged Care Group [RobotToday] [Upstarts Media]; disclosed financing that has moved from pre-seed to seed to a $23 million Series A announced in September 2025 [Andromeda Robotics, September 2025] [Crunchbase]; and visible signs of commercialization buildout, including a 400% warehouse expansion and open roles spanning U.S. sales, behavior engineering, and field operations [SmartCompany] [Built In] [Indeed]. In plain terms, the company appears to be moving from proving that residents will engage with the robot to proving that operators will buy, deploy, and support it at multi-site level.
The public evidence also suggests the wedge is operationally sensible. Andromeda is not trying to automate clinical labor first. Abi is positioned around companionship, emotional interaction, and daily social and cognitive support in settings where loneliness, dementia care, and staff time constraints are already well understood by buyers [Andromeda Robotics] [mecwacare] [National Seniors Australia]. That makes the first budget conversation easier to imagine than a broader "general-purpose humanoid" pitch, because the use case is narrow enough for an operator to test and visible enough for families and staff to notice.
| Scenario | What happens | Catalyst | Why its plausible |
|---|---|---|---|
| Multi-site aged-care standard | Abi becomes a recurring procurement line for Australian aged-care groups, moving from single-home trials to network-wide deployment contracts | The mecwacare rollout across 22 homes becomes a reference deployment that de-risks adoption for other operators [RobotToday] | Andromeda already has public evidence of multi-site activity with mecwacare, plus earlier work with Allity and Medical & Aged Care Group [RobotToday] [Andromeda Robotics] [Upstarts Media] |
| Australia-to-U.S. replication | The company uses Australian proof points to win memory-care and senior-living groups in the U.S., where one successful operator can anchor a broader go-to-market motion | U.S. commercial hiring and the Eskaton partnership convert international expansion from announcement to repeatable sales motion [Built In] [Andromeda Robotics] | A U.S. sales role is publicly listed, and the company has already described Eskaton Village Carmichael as its first U.S. partnership after launching there in March [Built In] [Andromeda Robotics] |
| Companion robot platform | Abi evolves from a single hardware product into a configurable software and personality platform sold into multiple care settings | The planned Abi app and customizable archetypes improve fit across operators, resident profiles, and languages [Andromeda Robotics] | Company materials describe personality customization, customer-selectable archetypes, and adaptation to resident personality, ability, and language, which points to a platform path if buyers value configurability [Andromeda Robotics] |
What compounding looks like is straightforward if the company can keep deployments working. Each additional site should create three assets: more operator trust, more behavioral data on what drives resident engagement, and more implementation know-how around onboarding, support, and staff workflows. There are early public hints that this loop may be starting, because Andromeda has moved beyond one-off publicity into larger operational capacity, including a larger warehouse footprint and role openings tied to robot behavior, decision-making, and field execution [SmartCompany] [Built In] [Indeed]. If that loop holds, the moat is less likely to come from the base model itself than from the combination of care-specific interaction data, deployment muscle, and reference customers that make procurement easier for the next provider.
There is also a distribution compounding effect in institutional care. A successful deployment in one network can matter disproportionately because aged-care procurement is reference-driven and multi-site by nature. The mecwacare footprint across 22 homes, and the reported use of Abi in three of Medical & Aged Care Group's 11 homes in Victoria, suggest that Andromeda is already selling into organizations where expansion can happen site by site rather than customer by customer [RobotToday] [Upstarts Media]. That is a more attractive shape than a pure direct-to-consumer robotics model, because one enterprise relationship can create many physical endpoints.
The size of the win is best framed through market share rather than near-term revenue claims, because public financial disclosure is still thin. If the eldercare robot market reaches $3.56 billion in 2026 as reported by RoboZaps, then a company that captured 5% of that market would correspond to roughly $178 million in annual revenue (estimated), calculated as $3.56 billion x 0.05 [RoboZaps, 2026]. At 10% share, the figure would be about $356 million in annual revenue (estimated) [RoboZaps, 2026]. If the "Australia-to-U.S. replication" scenario plays out and the business is valued more like a scaled category leader than a niche hardware vendor, the public reference point of a $100 million valuation attached to the September 2025 Series A shows the market already ascribes meaningful option value to the company [Business News Australia, September 2025] [MassRobotics]. That does not establish fair value, but it does show the upside case is being underwritten as a platform outcome rather than a small device business. On that basis, a multi-hundred-million-dollar enterprise value is a credible upside frame, and a billion-dollar outcome is conceivable (scenario, not a forecast) if Andromeda proves repeatable multi-country deployments and software-like expansion within each operator.
Single-source, plausible -- Section relies on a mix of company announcements and partial third-party corroboration, with stronger support for funding and named deployments than for market sizing or valuation framing.
Sources
From the public record
[Andromeda Robotics, September 2025] Series A funding news: Fuel for our zero loneliness vision | https://andromedarobotics.ai/post/series-a-funding-news-fuel-for-our-zero-loneliness-vision
[RobotToday] Andromeda Robotics | https://robottoday.com/suppliers-discovery/andromeda-robotics
[Built In] Andromeda Jobs + Careers | https://builtin.com/company/andromeda/jobs
[SmartCompany] Andromeda Robotics raises $3 million seed round to scale ... | https://andromedarobotics.ai/post/andromeda-abi-robot-smartcompany
[Forbes, 2022] Grace Brown | https://www.forbes.com/profile/grace-brown/
[Andromeda Robotics] Personalised robot companions for aged care & assisted living residents | https://andromedarobotics.ai/
[National Seniors Australia] How social robots are transforming aged care | https://nationalseniors.com.au/news/latest/how-social-robots-are-transforming-aged-care
[Upstarts Media] MACG currently works with Abi robots across three of its 11 aged care homes in Melbourne’s state of Victoria | https://upstarts.com.au/humanoid-robot-aged-care/
[mecwacare] Innovative social robot trial expands across mecwacare homes | https://www.mecwacare.org.au/news/innovative-social-robot-trial-expands-across-mecwacare-homes/
[Crunchbase] Andromeda Robotics | https://www.crunchbase.com/organization/andromeda-robotics
[Forbes] Grace Brown | https://www.forbes.com/profile/grace-brown/
[Indeed] Andromeda Robotics Jobs and Careers | https://au.indeed.com/cmp/Andromeda-Robotics/jobs
[Reuters, July 2025] Meet Abi, the humanoid robot bringing empathy to care homes | https://jp.reuters.com/video/watch/idRW203023072025RP1/
[diginomica] Meet Abi, the robot companion bringing joy to Australian care homes | https://diginomica.com/meet-abi-robot-companion-bringing-joy-australian-care-homes
[RoboZaps, 2026] Eldercare robot market is valued at $3.56 billion in 2026, growing at 12.5% CAGR | https://robozaps.com/
[Business News Australia, September 2025] Andromeda Robotics hits $100 million valuation on $23 million Series A raise | https://www.businessnewsaustralia.com/articles/andromeda-robotics-hits-100-million-valuation-on--23-million-series-a-raise.html
[MassRobotics] Andromeda Robotics raises $23 million Series A to tackle loneliness with humanoid companion robots | https://www.massrobotics.org/andromeda-robotics-raises-23-million-series-a/
[Forbes Australia] Grace Brown is a mechatronics engineer who has been building robots since 15 | https://www.forbes.com.au/
[Andromeda Robotics] Andromeda Robotics announces world-first aged care … | https://andromedarobotics.ai/post/andromeda-abi-robot-itwire
[Andromeda Robotics] News about Abi and our industry | https://andromedarobotics.ai/news
Articles about Andromeda Robotics
- A Robot Designed for Loneliness Is Scaling Across Australia's Care Homes — The Melbourne startup, now valued at $100 million, is using emotional interaction as its initial market wedge before any clinical claims.